186 related articles for article (PubMed ID: 8678968)
1. Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction.
Wängberg B; Westberg G; Tylén U; Tisell L; Jansson S; Nilsson O; Johansson V; Scherstén T; Ahlman H
World J Surg; 1996 Sep; 20(7):892-9; discussion 899. PubMed ID: 8678968
[TBL] [Abstract][Full Text] [Related]
2. The role of surgery in patients with advanced midgut carcinoid tumours.
Ahlman H
Digestion; 1996; 57 Suppl 1():86-7. PubMed ID: 8813479
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study.
Jacobsen MB; Hanssen LE; Kolmannskog F; Schrumpf E; Vatn MH; Bergan A
Scand J Gastroenterol; 1995 Aug; 30(8):789-96. PubMed ID: 7481548
[TBL] [Abstract][Full Text] [Related]
4. Treatment of liver metastases of carcinoid tumors.
Ahlman H; Westberg G; Wängberg B; Nilsson O; Tylén U; Scherstén T; Tisell LE
World J Surg; 1996 Feb; 20(2):196-202. PubMed ID: 8661817
[TBL] [Abstract][Full Text] [Related]
5. Management of disseminated midgut carcinoid tumours.
Ahlman H; Wängberg B; Jansson S; Stenqvist O; Geterud K; Tylén U; Caidahl K; Scherstén T; Tisell LE
Digestion; 1991; 49(2):78-96. PubMed ID: 1724766
[TBL] [Abstract][Full Text] [Related]
6. Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors.
Schell SR; Camp ER; Caridi JG; Hawkins IF
J Gastrointest Surg; 2002; 6(5):664-70. PubMed ID: 12399054
[TBL] [Abstract][Full Text] [Related]
7. Embolisation therapy in the midgut carcinoid syndrome: just tumour ischaemia?
Wängberg B; Geterud K; Nilsson O; Jansson S; Dahlström A; Tylén U; Ahlman H
Acta Oncol; 1993; 32(2):251-6. PubMed ID: 7686767
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor imaging: predictive and prognostic considerations.
Anthony LB; Martin W; Delbeke D; Sandler M
Digestion; 1996; 57 Suppl 1():50-3. PubMed ID: 8813470
[TBL] [Abstract][Full Text] [Related]
9. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
Janson ET; Westlin JE; Ohrvall U; Oberg K; Lukinius A
J Nucl Med; 2000 Sep; 41(9):1514-8. PubMed ID: 10994731
[TBL] [Abstract][Full Text] [Related]
10. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
[TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide and somatostatin receptor scintigraphy for differential diagnosis of hepatic carcinoid metastasis.
Kurtaran A; Raderer M; Müller C; Prokesch R; Kaserer K; Eibenberger K; Koperna K; Niederle B; Virgolini I
J Nucl Med; 1997 Jun; 38(6):880-1. PubMed ID: 9189133
[TBL] [Abstract][Full Text] [Related]
12. [Isotopic scan with somatostatin receptors in a case of recurrent carcinoid tumor. Relevance of tomographic detection].
Bernà Roqueta L; Martín Marimón JC; Martín Martínez J
Rev Esp Med Nucl; 2002 Apr; 21(2):123-4. PubMed ID: 11879622
[No Abstract] [Full Text] [Related]
13. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours.
Kölby L; Persson G; Franzén S; Ahrén B
Br J Surg; 2003 Jun; 90(6):687-93. PubMed ID: 12808615
[TBL] [Abstract][Full Text] [Related]
14. [The scintigraphy of somatostatin receptors in the carcinoid tumor].
Banzo J; Abós MD; Prats E; Delgado M; Razola P; García S; Gomollón F; García F
Rev Esp Med Nucl; 2001 Feb; 20(1):11-8. PubMed ID: 11181324
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of 5-hydroxyindoloacetic acid excretion in urine in patients with small intestine neuroendocrine neoplasm and carcinoid syndrome treated with somatostatin analogues.
Gut P; Ruchała M
Neuro Endocrinol Lett; 2019 Dec; 40(7-8):315-318. PubMed ID: 32304367
[TBL] [Abstract][Full Text] [Related]
16. [Resection of carcinoid tumors of the small intestine is still indicated in the presence of disseminated hepatic metastases].
Partensky C; Landraud R; Velecela E; Souquet JC
Ann Chir; 1990; 44(1):34-8. PubMed ID: 1689980
[TBL] [Abstract][Full Text] [Related]
17. Management of midgut carcinoids.
Akerström G; Hellman P; Hessman O; Osmak L
J Surg Oncol; 2005 Mar; 89(3):161-9. PubMed ID: 15719373
[TBL] [Abstract][Full Text] [Related]
18. Persistent low urinary excretion of 5-HIAA is a marker for favourable survival during follow-up in patients with disseminated midgut carcinoid tumours.
van der Horst-Schrivers AN; Post WJ; Kema IP; Links TP; Willemse PH; Wymenga AN; de Vries EG
Eur J Cancer; 2007 Dec; 43(18):2651-7. PubMed ID: 17825550
[TBL] [Abstract][Full Text] [Related]
19. Hepatic artery embolization for treatment of patients with metastatic carcinoid tumors: a commentary.
Norton JA; Kerlan RK
Cancer J; 2003; 9(4):241-3. PubMed ID: 12967132
[No Abstract] [Full Text] [Related]
20. SMS 201-995 and provocation tests in preparation of patients with carcinoids for surgery or hepatic arterial embolization.
Ahlman H; Ahlund L; Dahlström A; Martner J; Stenqvist O; Tylén U
Anesth Analg; 1988 Dec; 67(12):1142-8. PubMed ID: 2461665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]